Evidence map›Paper›PMID 25896816›Full record

ArticleMolecular imaging and biology2015

Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.

Ning Guo, Fan Zhang, Xiaomeng Zhang, Jinxia Guo, Lixin Lang, Dale O Kiesewetter, Gang Niu, Quanzheng Li, Xiaoyuan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. [Molecular imaging and biology · 2019
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ning GuoCenter for Advanced Medical Imaging Sciences, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, 02114, USA.
Fan ZhangCenter for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China, 361005.
Xiaomeng ZhangCenter for Advanced Medical Imaging Sciences, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, 02114, USA.
Jinxia GuoCenter for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China, 361005.
Lixin LangLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 35A Convent Dr, GD937, Bethesda, MD, 20892-3759, USA.
Dale O KiesewetterLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 35A Convent Dr, GD937, Bethesda, MD, 20892-3759, USA.
Gang NiuLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 35A Convent Dr, GD937, Bethesda, MD, 20892-3759, USA.
Quanzheng LiCenter for Advanced Medical Imaging Sciences, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, 02114, USA. Li.quanzheng@mgh.harvard.edu.
Xiaoyuan ChenLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 35A Convent Dr, GD937, Bethesda, MD, 20892-3759, USA. shawn.chen@nih.gov.

Funding

Laboratory of Molecular Imaging and NanomedicineZIAEB000073 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CHEN, XIAOYUAN · 2010 to 2020
$32.8M
Quantitative Methods for Clinical Whole Body Dynamic PETR01EB013293 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI LI, QUANZHENG · 2012 to 2015
$1.5M
An Integrated Statistical Framework for Lesion Detection Using Dynamic PETR21CA149587 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LI, QUANZHENG · 2010 to 2011
$383k
Intramural NIH HHS Z99 EB999999Intramural NIH HHS ZIA EB000073NCI NIH HHS R21 CA149587NCI NIH HHS R21CA149587NIBIB NIH HHS R01 EB013293NIBIB NIH HHS R01EB013293
6 · The paper itself

Abstract

purposeThe purpose of this study is to evaluate the early response of tumors to a vascular-disrupting agent (VDA) VEGF121/recombinant toxin gelonin (rGel) using dynamic [(18)F]FPPRGD2 positron emission tomography (PET) and kinetic parameter estimation. PROCEDURES: Two tumor xenograft models: U87MG (highly vascularized) and A549 (moderately vascularized), were selected, and both were randomized into treatment and control groups. Sixty-minute dynamic PET scans with [(18)F]FPPRGD2 that targets to integrin αvβ3 were performed at days 0 (baseline), 1, and 3 since VEGF121/rGel treatment started. Dynamic PET-derived binding potential (BPND) and parametric maps were compared with tumor uptake (%ID/g) and the static PET image at 1 h after the tracer administration.

resultsThe growth of U87MG tumor was obviously delayed upon VEGF121/rGel treatment. A549 tumor was not responsive to the same treatment. BPND of treated U87MG tumors decreased significantly at day 1 (p < 0.05), and the difference was more significant at day 3 (p < 0.01), compared with the control group. However, the tracer uptake (%ID/g) derived from static images at 1-h time point did not show significant difference between the treated and control tumors until day 3. Little difference in tracer uptake (%ID/g) or BPND was found between treated and control A549 tumors. Considering the tracer retention in tumor and the slower clearance due to damaged tumor vasculature after treatment, BPND representing the actual specific binding portion appears to be more sensitive and accurate than the semiquantitative parameters (such as %ID/g) derived from static images to assess the early response of tumor to VDA treatment.

conclusionsQuantitative analysis based on dynamic PET with [(18)F]FPPRGD2 shows advantages in distinguishing effective from ineffective treatment during the course of VEGF121/rGel therapy at early stage and is therefore more sensitive in assessing therapy response than static PET.

Indexed as

Angiogenesis InhibitorsAnimalsBrain NeoplasmsCell Line, TumorFemaleGlioblastomaHeterograftsHumansLung NeoplasmsMiceMice, NudePositron-Emission TomographyVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor A[18F]FPPRGD2Dynamic PETIntegrin αvβ3Vascular-disrupting agent

Identifiers

PMID25896816
PMCPMC5218587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.